MODL yields 0.77% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, MODL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MODL + ABBV for your $10,000?
The VictoryShares WestEnd U.S. Sector ETF seeks to achieve favorable returns through active sector selection and avoidance, based on the team’s evaluation of the macroeconomic and market environment. The team implements its active sector selection and avoidance process through sector exposures using individual stocks. This ETF typically allocates to four to six economic sectors at any given time, with the maximum exposure to a single sector being no more than 35% of the Fund's net assets at the time of purchase. Portfolio Managers Fritz Porter, CFA Co-CIO, Portfolio Manager 18th year at WestEnd Advisors | 26 years of experience Ty Peebles, CFA, Co-CIO, Portfolio Manager 12th year at WestEnd Advisors | 15 years of experience Ned Durden, CIS, Portfolio Manager 19th year at WestEnd Advisors | 26 years of experience Jacob Buchanan, CFA, Portfolio Manager 8th year at WestEnd Advisors | 9 years of experience
Full MODL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.